Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative COI-B for Colorectal Liver Metastases
NCT02086656Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jun 2013
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in Colorectal cancer with liver metastases (CRLM), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Pathological Response Rate (TRG). Started Jun 2013; status: completed.
02
Drugs
bevacizumab
03
Conditions
Colorectal cancer with liver metastases (CRLM)
Beyond the preview
Go deeper on NCT02086656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02086656.